Mathematical models: A key to understanding HIV envelope interactions?

Journal of Immunological Methods

Volumn 398-399, Issue 1, 2013, Pages 1-18

  Magnus, Carsten ^a   Brandenberg, Oliver F ^a   Rusert, Peter ^a   Trkola, Alexandra ^a   Regoes, Roland R ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

Epitope masking by variable loops 1 and 2; Human immunodeficiency virus envelope interactions; Mathematical models; Quaternary epitopes

Indexed keywords

EPITOPE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIGEN BINDING; ANTIGEN STRUCTURE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MATHEMATICAL MODEL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTECTION; VARIABLE LOOP 1; VARIABLE LOOP 2; VARIABLE LOOP 3; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS SPIKE;

EPITOPE MASKING BY VARIABLE LOOPS 1 AND 2; HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE INTERACTIONS; MATHEMATICAL MODELS; QUATERNARY EPITOPES;

AIDS VACCINES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; MODELS, IMMUNOLOGICAL; PROTEIN STRUCTURE, SECONDARY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84888206204     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.09.002     Document Type: Article

References (91)

1. Bar K.J., Tsao C.Y., Iyer S.S., Decker J.M., Yang Y., Bonsignori M., Chen X., Hwang K.K., Montefiori D.C., Liao H.X., Hraber P., Fischer W., Li H., Wang S., Sterrett S., Keele B.F., Ganusov V.V., Perelson A.S., Korber B.T., Georgiev I., McLellan J.S., Pavlicek J.W., Gao F., Haynes B.F., Hahn B.H., Kwong P.D., Shaw G.M. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog. 2012, 8:e1002721.
2. Bunnik E.M., Euler Z., Welkers M.R.A., Boeser-Nunnink B.D.M., Grijsen M.L., Prins J.M., Schuitemaker H. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat. Med. 2010, 16:991.
3. Burton D.R., Stanfield R.L., Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14943.
4. Burton D.R., Ahmed R., Barouch D.H., Butera S.T., Crotty S., Godzik A., Kaufmann D.E., McElrath M.J., Nussenzweig M.C., Pulendran B., Scanlan C.N., Schief W.R., Silvestri G., Streeck H., Walker B.D., Walker L.M., Ward A.B., Wilson I.A., Wyatt R. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012, 12:396.
5. Burton D.R., Poignard P., Stanfield R.L., Wilson I.A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012, 337:183.
6. Cao J., Sullivan N., Desjardin E., Parolin C., Robinson J., Wyatt R., Sodroski J. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J. Virol. 1997, 71:9808.
7. Chackerian B., Rudensey L., Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J. Virol. 1997, 71:7719.
8. Chen L., Kwon Y.D., Zhou T., Wu X., O'Dell S., Cavacini L., Hessell A.J., Pancera M., Tang M., Xu L., Yang Z.Y., Zhang M.Y., Arthos J., Burton D.R., Dimitrov D.S., Nabel G.J., Posner M.R., Sodroski J., Wyatt R., Mascola J.R., Kwong P.D. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009, 326:1123.
9. Chohan B., Lang D., Sagar M., Korber B., Lavreys L., Richardson B., Overbaugh J. Selection for human immunodeficiency virus type I envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J. Virol. 2005, 79:6528.
10. Curlin M.E., Zioni R., Hawes S.E., Liu Y., Deng W., Gottlieb G.S., Zhu T., Mullins J.I. HIV-1 envelope subregion length variation during disease progression. PLoS Pathog. 2010, 6:e1001228.
11. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., Allen S., Hunter E. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004, 303:2019.
12. Doms R.W., Earl P.L., Chakrabarti S., Moss B. Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain. J. Virol. 1990, 64:3537.
13. Doores K.J., Burton D.R. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. Journal Of Virology 2010, 84:10510.
14. Doria-Rose N.A., Klein R.M., Daniels M.G., O'Dell S., Nason M., Lapedes A., Bhattacharya T., Migueles S.A., Wyatt R.T., Korber B.T., Mascola J.R., Connors M. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 2010, 84:1631.
15. Doria-Rose N.A., Georgiev I., O'Dell S., Chuang G.Y., Staupe R.P., McLellan J.S., Gorman J., Pancera M., Bonsignori M., Haynes B.F., Burton D.R., Koff W.C., Kwong P.D., Mascola J.R. A short segment of the HIV-1 gp120 V1/V2 Region is a major determinant of resistance to V1/V2 neutralizing antibodies. J. Virol. 2012, 86:8319.
16. Fox D., Balfe P., Palmer C., May J., Arnold C., McKeating J. Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site. J. Virol. 1997, 71:759.
17. Gallo S.A., Finnegan C.M., Viard M., Raviv Y., Dimitrov A., Rawat S.S., Puri A., Durell S., Blumenthal R. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 2003, 1614:36.
18. Goo L., Milligan C., Simonich C.A., Nduati R., Overbaugh J. Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope. J. Virol. 2012, 86:9566.
19. Gorny M.K., Stamatatos L., Volsky B., Revesz K., Williams C., Wang X.H., Cohen S., Staudinger R., Zolla-Pazner S. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 2005, 79:5232.
20. Groenink M., Fouchier R.A., Broersen S., Baker C.H., Koot M., van't Wout A.B., Huisman H.G., Miedema F., Tersmette M., Schuitemaker H. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993, 260:1513.
21. Harrington P.R., Nelson J.A.E., Kitrinos K.M., Swanstrom R. Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection. J. Virol. 2007, 81:5413.
22. Herrera C., Klasse P.J., Kibler C.W., Michael E., Moore J.P., Beddows S. Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex. Virology 2006, 351:121.
23. Hoxie J.A. Toward an antibody-based HIV-1 vaccine. Annu Rev Med 2010, 61:135.
24. Hu G., Liu J., Taylor K.A., Roux K.H. Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J. Virol. 2011, 85:2741.
25. Hughes E.S., Bell J.E., Simmonds P. Investigation of population diversity of human immunodeficiency virus type 1 in vivo by nucleotide sequencing and length polymorphism analysis of the V1/V2 hypervariable region of env. J. Gen. Virol. 1997, 78(Pt 11):2871.
26. Johnson W.E., Morgan J., Reitter J., Puffer B.A., Czajak S., Doms R.W., Desrosiers R.C. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J. Virol. 2002, 76:2075.
27. Julien J.P., Lee J.H., Cupo A., Murin C.D., Derking R., Hoffenberg S., Caulfield M.J., King C.R., Marozsan A.J., Klasse P.J., Sanders R.W., Moore J.P., Wilson I.A., Ward A.B. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(11):4351.
28. Klasse P.J. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 2007, 369:245.
29. Klasse P.J., Sattentau Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 2002, 83:2091.
30. Koito A., Harrowe G., Levy J.A., Cheng-Mayer C. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J. Virol. 1994, 68:2253.
31. Kolchinsky P., Kiprilov E., Bartley P., Rubinstein R., Sodroski J. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J. Virol. 2001, 75:3435.
32. Krachmarov C., Pinter A., Honnen W.J., Gorny M.K., Nyambi P.N., Zolla-Pazner S., Kayman S.C. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B V3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J. Virol. 2005, 79:780.
33. Kwon Y.D., Finzi A., Wu X., Dogo-Isonagie C., Lee L.K., Moore L.R., Schmidt S.D., Stuckey J., Yang Y., Zhou T., Zhu J., Vicic D.A., Debnath A.K., Shapiro L., Bewley C.A., Mascola J.R., Sodroski J.G., Kwong P.D. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(15):5663.
34. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity 2012, 37:412.
35. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W., Robinson J., Van Ryk D., Wang L., Burton D.R., Freire E., Wyatt R., Sodroski J., Hendrickson W.A., Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678.
36. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franti M., Binley J., Vivona V., Grundner C., Huang C.C., Venturi M., Petropoulos C.J., Wrin T., Dimitrov D.S., Robinson J., Kwong P.D., Wyatt R.T., Sodroski J., Burton D.R. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 2003, 77:10557.
37. Lamers S.L., Sleasman J.W., She J.X., Barrie K.A., Pomeroy S.M., Barrett D.J., Goodenow M.M. Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo. J. Virol. 1993, 67:3951.
38. Li Y., Cleveland B., Klots I., Travis B., Richardson B.A., Anderson D., Montefiori D., Polacino P., Hu S.L. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 2008, 82:638.
39. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109.
40. Liu L., Cimbro R., Lusso P., Berger E.A. Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:20148.
41. Losman B., Bolmstedt A., Schonning K., Bjorndal A., Westin C., Fenyo E.M., Olofsson S. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. AIDS Res. Hum. Retroviruses 2001, 17:1067.
42. Ly A., Stamatatos L. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J. Virol. 2000, 74:6769.
43. Magnus C., Regoes R.R. Estimating the stoichiometry of HIV neutralization. PLoS Comput. Biol. 2010, 6:e1000713. 10.1371/journal.pcbi.1000713.
44. Magnus C., Regoes R.R. Analysis of the subunit stoichiometries in viral entry. PLoS One 2012, 7:e33441.
45. Magnus C., Rusert P., Bonhoeffer S., Trkola A., Regoes R.R. Estimating the stoichiometry of human immunodeficiency virus entry. J. Virol. 2009, 83:1523.
46. Mao Y., Wang L., Gu C., Herschhorn A., Xiang S.H., Haim H., Yang X., Sodroski J. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat. Struct. Mol. Biol. 2012, 19(9):893.
47. Mao Y., Wang L., Gu C., Herschhorn A., Désormeaux A., Finzi A., Xiang S.H., Sodroski J.G. Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(30):12438.
48. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413.
49. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., O'Dell S., Patel N., Shahzad-Ul-Hussan S., Yang Y., Zhang B., Zhou T., Zhu J., Boyington J.C., Chuang G.Y., Diwanji D., Georgiev I., Do Kwon Y., Lee D., Louder M.K., Moquin S., Schmidt S.D., Yang Z.Y., Bonsignori M., Crump J.A., Kapiga S.H., Sam N.E., Haynes B.F., Burton D.R., Koff W.C., Walker L.M., Phogat S., Wyatt R., Orwenyo J., Wang L.X., Arthos J., Bewley C.A., Mascola J.R., Nabel G.J., Schief W.R., Ward A.B., Wilson I.A., Kwong P.D. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336.
50. Montefiori D.C.D. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 2008, 485:395.
51. Morikita T., Maeda Y., Fujii S., Matsushita S., Obaru K., Takatsuki K. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism. AIDS Res. Hum. Retroviruses 1997, 13:1291.
52. O'Rourke S.M., Schweighardt B., Phung P., Fonseca D.P., Terry K., Wrin T., Sinangil F., Berman P.W. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J. Virol. 2010, 84:11200.
53. Palmer C., Balfe P., Fox D., May J., Frederiksson R., Fenyo E., McKeating J. Functional characterization of the V1V2 region of human immunodeficiency virus type 1. Virology 1996, 220:436.
54. Pastore C., Nedellec R., Ramos A., Pontow S., Ratner L., Mosier D.E. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J. Virol. 2006, 80:750.
55. Pinter A., Honnen W.J., He Y., Gorny M.K., Zolla-Pazner S., Kayman S.C. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 2004, 78:5205.
56. Quinones-Kochs M.I., Buonocore L., Rose J.K. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J. Virol. 2002, 76:4199.
57. Ren X., Sodroski J., Yang X. An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins. J. Virol. 2005, 79:5616. 10.1128/JVI.79.9.5616-5624.2005.
58. Ritola K., Pilcher C.D., Fiscus S.A., Hoffman N.G., Nelson J.A., Kitrinos K.M., Hicks C.B., Eron J.J., Swanstrom R. Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J. Virol. 2004, 78:11208.
59. Robey W., Safai B., Oroszlan S., Arthur L., Gonda M., Gallo R., Fischinger P. Characterization of envelope and core structural gene-products of HTLV-III with sera from AIDS patients. Science 1985, 228:593.
60. Robinson J.E., Franco K., Elliott D.H., Maher M.J., Reyna A., Montefiori D.C., Zolla-Pazner S., Gorny M.K., Kraft Z., Stamatatos L. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J. Virol. 2010, 84:3443.
61. Ross T.M., Cullen B.R. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7682.
62. Rusert P., Krarup A., Magnus C., Brandenberg O.F., Weber J., Ehlert A.K., Regoes R.R., Guenthard H.F., Trkola A. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J. Exp. Med. 2011, 208:1419.
63. Sagar M., Wu X., Lee S., Overbaugh J. Human immunodeficiency virus type 1V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 2006, 80:9586.
64. Salzwedel K., Berger E. Cooperative subunit interactions within the oligomeric envelope glycoprotein of hiv-1: functional complementation of specific defects in gp120 and gp41. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12794.
65. Sattentau Q.J., Moore J.P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 1995, 182:185.
66. Saunders C.J., McCaffrey R.A., Zharkikh I., Kraft Z., Malenbaum S.E., Burke B., Cheng-Mayer C., Stamatatos L. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J. Virol. 2005, 79:9069.
67. Schonning K., Lund O., Lund O.S., Hansen J.E.S. Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1. J. Virol. 1999, 8364-8370.
68. Shibata J., Yoshimura K., Honda A., Koito A., Murakami T., Matsushita S. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J. Virol. 2007, 81:3757.
69. Shioda T., Levy J.A., Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 1991, 349:167.
70. Stamatatos L., Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J. Virol. 1998, 72:7840.
71. Stamatatos L., Wiskerchen M., Cheng-Mayer C. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. AIDS Res. Hum. Retroviruses 1998, 14:1129.
72. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat. Med. 2009, 15:866.
73. Sullivan N., Thali M., Furman C., Ho D.D., Sodroski J. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J. Virol. 1993, 67:3674.
74. Toohey K., Wehrly K., Nishio J., Perryman S., Chesebro B. Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology 1995, 213:70.
75. Veronese F., Devico A., Copeland T., Oroszlan S., Gallo R., Sarngadharan M. Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 1985, 229:1402.
76. Walker L., Phogat S., Chan-Hui P., Wagner D., Phung P., Goss J., Wrin T., Simek M., Fling S., Mitcham J., Lehrman J., Priddy F., Olsen O., Frey S., Hammond P., Kaminsky S., Zamb T., Moyle M., Koff W., Poignard P., Burton D. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285.
77. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 1-10.
78. Wei X., Decker J., Wang S., Hui H., Kappes J., Wu X., Salazar-Gonzalez J., Salazar M., Kilby J., SAAG M., Komarova N., Nowak M., HAHN B., Kwong P., SHAW G. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307.
79. White T.A., Bartesaghi A., Borgnia M.J., Meyerson J.R., de la Cruz M.J.V., Bess J.W., Nandwani R., Hoxie J.A., Lifson J.D., Milne J.L.S., Subramaniam S. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 2010, 6.
80. Wilen C.B., Tilton J.C., Doms R.W. Molecular mechanisms of HIV entry. Adv. Exp. Med. Biol. 2012, 726:223.
81. Wolk T., Schreiber M. N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med. Microbiol. Immunol. 2006, 195:165.
82. Wu X., Zhou T., O'Dell S., Wyatt R.T., Kwong P.D., Mascola J.R. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J. Virol. 2009, 83:10892.
83. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884.
84. Wyatt R., Sullivan N., Thali M., Repke H., Ho D., Robinson J., Posner M., Sodroski J. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 1993, 67:4557.
85. Wyatt R., Moore J., Accola M., Desjardin E., Robinson J., Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 1995, 69:5723.
86. Yang Z.Y., Chakrabarti B.K., Xu L., Welcher B., Kong W.P., Leung K., Panet A., Mascola J.R., Nabel G.J. Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J. Virol. 2004, 78:4029.
87. Yang X., Kurteva S., Lee S., Sodroski J. Stoichiometry of antibody neutralization of Human Immunodeficiency Virus type 1. J. Virol. 2005, 79:3500.
88. Yang X., Kurteva S., Ren X., Lee S., Sodroski J. Stoichiometry of envelope glycoprotein trimers in the entry of Human Immunodeficiency Virus type 1. J. Virol. 2005, 79:12132.
89. Yang X., Kurteva S., Ren X., Lee S., Sodroski J. Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. J. Virol. 2006, 80:4388.
90. Yang X., Lipchina I., Cocklin S., Chaiken I., Sodroski J. Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization. J. Virol. 2006, 80:11404. 10.1128/JVI.01102-06.
91. Zhu P., Liu J., Bess J., Chertova E., Lifson J.D., Grise H., Ofek G.A., Taylor K.A., Roux K.H. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441:847.